Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 17010-17011 [2017-06979]
Download as PDF
<![CDATA[
nlaroche on DSK30NT082PROD with NOTICES
17010
Federal Register / Vol. 82, No. 66 / Friday, April 7, 2017 / Notices
undertaken in regards to their
participation in this Challenge that
conflict with the Challenge rules, terms
and conditions may result in
disqualification of the Applicant’s
submission.
• Upon submission, each Applicant
warrants that he or she is the sole author
and owner of the work and any
pertinent Intellectual Property (IP)
rights, that the work is wholly original
of the Applicant (or is an improved
version of an existing work that the
Applicant has sufficient rights to use—
including the substantial improvement
of existing open-source work), and that
it does not infringe any copyright or any
other rights of any third party of which
Applicant is aware. Each Applicant also
warrants that the work is free of security
threats and/or malware.
• Applicants retain ownership of the
data that they develop and deliver
under the scope of the Challenge,
including any software, research or
other intellectual property (‘‘IP’’) that
they develop in connection therewith.
Applicants agree to grant a license to the
Federal Agency sponsor (CDC) for the
use of the IP developed in connection
with the Challenge as set forth herein.
• Each Applicant must clearly
delineate any Intellectual Property (IP)
and/or confidential commercial
information contained in a submission
that is owned by the Applicant, and
which the Applicant wishes to protect
as proprietary data.
• Upon completion of the Challenge
period, applicants consents to grant
CDC an unlimited, non-exclusive,
royalty-free, worldwide license and
right to reproduce, publically perform,
publically display, and use the
Submission and to publically perform
and publically display the Submission,
including, without limitation, for
promotional purposes relating to the
Challenge.
• All materials submitted to CDC as
part of a submission become CDC
agency records. Any confidential
commercial or financial information
contained in a submission must be
clearly designated at the time of
submission.
• If the Submission includes any
third party works (such as third party
content or open source code), Applicant
must be able to provide, upon request,
documentation of all appropriate
licenses and releases for use of such
third party works. If Applicant cannot
provide documentation of all required
licenses and releases, Federal Agency
sponsors reserve the right, at their sole
discretion, to disqualify the applicable
Submission. Conversely, they may seek
to secure the licenses and releases and
VerDate Sep<11>2014
14:52 Apr 06, 2017
Jkt 241001
allow the applicable Submission to
remain in the Challenge, while reserving
all applicable Federal agency rights with
respect to such licenses and releases.
• FOIA: Submitters will be notified of
any Freedom of Information Act (FOIA)
requests for their materials which have
been clearly designated as confidential
commercial or financial information or
trade secret in accordance with 45 CFR
5.65.
Privacy
If Contestants choose to provide CDC
with personal information by registering
or filling out the submission form
through the https://
envirohealthchallenge.com Web site,
that information is used to respond to
Contestants in matters regarding their
submission, announcements of entrants,
finalists, and winners of the Contest.
Information is not collected for
commercial marketing. Winners are
permitted to cite that they won this
contest.
General Conditions
CDC reserves the right to cancel,
suspend, and/or modify the Contest, or
any part of it, for any reason, at CDC’s
sole discretion. If the Challenge is
cancelled, suspended, or modified, CDC
will inform the public through the
publication of a notice in the Federal
Register and a posting on the Challenge
Web site.
Participation in this Contest
constitutes a contestants’ full and
unconditional agreement to abide by the
Contest’s terms and conditions found at
www.envirohealthchallenge.com or
www.Challenge.gov.
Understanding Provision of Confidential
Sexual Health Services to Adolescents.
Time and Date: 10:00 a.m.–6:00 p.m.,
EDT, May 10, 2017 (Closed).
Place:Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Understanding Provision of
Confidential Sexual Health Services to
Adolescents’’, SIP17–005.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–06982 Filed 4–6–17; 8:45 am]
BILLING CODE 4163–18–P
Authority: 15 U.S.C. 3719.
Dated: April 3, 2017.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2017–06974 Filed 4–6–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Special Interest Project (SIP) 17–005,
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Special Interest Projects (SIPs) 17–003,
Formative Study of Patient Navigators
with the National Breast and Cervical
Cancer Early Detection Program
(NBCCEDP) and the Colorectal Cancer
Control Program (CRCCP), and 17–004,
Assessing the Lifetime Economic
Burden in Younger, Midlife, and Older
Women with Metastatic Breast Cancer.
E:\FR\FM\07APN1.SGM
07APN1
Federal Register / Vol. 82, No. 66 / Friday, April 7, 2017 / Notices
Time and Date: 10:00 a.m.–6:00 p.m.,
EDT, May 9, 2017 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Formative Study of Patient Navigators
with the National Breast and Cervical
Cancer Early Detection Program
(NBCCEDP) and the Colorectal Cancer
Control Program (CRCCP)’’, SIP 17–003
and ‘‘Assessing the Lifetime Economic
Burden in Younger, Midlife, and Older
Women with Metastatic Breast Cancer’’,
SIP 17–004.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–06979 Filed 4–6–17; 8:45 am]
a.m.–5:00 p.m., EDT, May 12, 2017
(Closed).
Place: The Georgian Terrace, 659
Peachtree Street NE., Atlanta, Georgia
30308.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Research Grant for Preventing Violence
and Violence Related Injury (R01)’’,
RFA–CE–17–003.
Contact Person for More Information:
Kimberly Leeks, Ph.D., M.P.H.,
Scientific Review Officer, CDC, 4770
Buford Highway NE., Mailstop F78,
Atlanta, Georgia 30341–3717,
Telephone: (770) 488–5964.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
ACTION:
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Antimicrobial Drugs
Advisory Committee. The general
function of the committee is to provide
advice and recommendations to the
Agency on FDA’s regulatory issues. The
meeting will be open to the public. FDA
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–06984 Filed 4–6–17; 8:45 am]
BILLING CODE 4163–18–P
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2017–N–1813]
Centers for Disease Control and
Prevention
nlaroche on DSK30NT082PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement,
RFA–CE–17–003, Research Grant for
Preventing Violence and Violence
Related Injury (R01).
Times and Dates: 08:00 a.m.–5:00
p.m., EDT, May 11, 2017 (Closed) 8:00
VerDate Sep<11>2014
17:15 Apr 06, 2017
Jkt 241001
is establishing a docket for public
comment on this document.
DATES: The meeting will be held on
April 13, 2017, from 8:30 a.m. to 5 p.m.
The docket number is FDA–2017–N–
1813. The docket will close on April 12,
2017. Comments received on or before
April 10, 2017, will be provided to the
committee. Comments received after
that date will be taken into
consideration by the Agency.
ADDRESSES: Tommy Douglas Conference
Center, the Ballroom, 10000 New
Hampshire Ave., Silver Spring, MD
20903. The conference center’s
telephone number is 240–645–4000.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
You may submit comments as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
17011
Antimicrobial Drugs Advisory
Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice; establishment of public
docket; request for comments.
SUMMARY:
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
E:\FR\FM\07APN1.SGM
07APN1
]]>Agencies
[Federal Register Volume 82, Number 66 (Friday, April 7, 2017)]
[Notices]
[Pages 17010-17011]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06979]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to Special Interest Projects (SIPs) 17-003,
Formative Study of Patient Navigators with the National Breast and
Cervical Cancer Early Detection Program (NBCCEDP) and the Colorectal
Cancer Control Program (CRCCP), and 17-004, Assessing the Lifetime
Economic Burden in Younger, Midlife, and Older Women with Metastatic
Breast Cancer.
[[Page 17011]]
Time and Date: 10:00 a.m.-6:00 p.m., EDT, May 9, 2017 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Formative Study of Patient Navigators with the National Breast and
Cervical Cancer Early Detection Program (NBCCEDP) and the Colorectal
Cancer Control Program (CRCCP)'', SIP 17-003 and ``Assessing the
Lifetime Economic Burden in Younger, Midlife, and Older Women with
Metastatic Breast Cancer'', SIP 17-004.
Contact Person for More Information: Jaya Raman Ph.D., Scientific
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488-6511, kva5@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-06979 Filed 4-6-17; 8:45 am]
BILLING CODE 4163-18-P
